Seres therapeutics receives award of up to $3.6 million from carb-x to develop liquid formulation of ser-155

Liquid formulation has potential to expand patient access, including those in intensive care, to ser-155 for the prevention of bloodstream and antimicrobial resistant (amr) infections liquid formulation has potential to expand patient access, including those in intensive care, to ser-155 for the prevention of bloodstream and antimicrobial resistant (amr) infections
MCRB Ratings Summary
MCRB Quant Ranking